Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AGIL
- Sponsors AbbVie
- 16 Jun 2018 Results assessing the treatment responses in RA patients during 5-year Adalimumab treatment (n=4283) presented at the 19th Annual Congress of the European League Against Rheumatism
- 10 Oct 2017 Status changed from recruiting to completed.
- 31 Aug 2017 Planned End Date changed from 1 Aug 2017 to 15 Sep 2017.